npbuilds Board Readiness — Governance Literacy and Effective Service
A board seat — even an observer seat — is a high-leverage role with high downside risk if mishandled. The expectations are specific (fiduciary duties, governance protocols, board-CEO dynamics), the rhythms are formal (quarterly meetings with strict materials cycles), and the pattern-matching by other board members is fast. The senior MD stepping into board work without preparation often makes errors that take a year to recover from. This skill is the prep — what you need to know before the first board meeting.
Key Concepts
Director vs Observer vs Advisor
| Role | Voting | Fiduciary Duty | Compensation | Risk |
|---|---|---|---|---|
| Director | Yes | Yes (full) | Cash + equity ($30K–$200K+ per board) | Personal liability for company decisions |
| Observer | No | Limited | Cash + equity (often modest) | Lower; no voting |
| Advisor | No | None | Equity (typically) | Minimal |
Most senior MDs starting board work begin as observers or advisors before taking director seats. Each has distinct expectations and protocols.
Fiduciary Duties (For Directors)
A director's fiduciary duties:
- Duty of care — Make informed decisions; review materials, ask questions
- Duty of loyalty — Act in the company's interest, not personal interest; disclose conflicts
- Duty of good faith — Act honestly and reasonably
Directors who neglect these can face personal liability. The implications:
- Read every board package thoroughly before the meeting
- Disclose any conflict of interest, even apparent ones
- Don't trade on material non-public information
- Document major decisions and your reasoning
For observers, fiduciary duties are limited but professional duties (confidentiality, good faith) still apply.
The Board Materials Cycle
Most VC-backed boards run a quarterly cadence:
| Stage | Time Before Meeting | Activity |
|---|---|---|
| Materials draft | 2 weeks | CEO and team prepare board package |
| Board package distributed | 1 week | Sent to all directors and observers |
| Pre-read | 5–7 days | Directors read; ask clarifying questions |
| Board meeting | Day 0 | Live discussion (in-person or video) |
| Minutes distributed | 1 week after | Official record of decisions |
| Action follow-ups | Ongoing | Inter-meeting work between board and team |
The board member who reads the package the morning of the meeting is the bad board member. Read it the day it arrives.
What's in a Board Package
Standard contents for a venture-backed biotech board package:
- CEO update (narrative; 2–5 pages)
- Financial dashboard (cash, burn, runway, key metrics)
- Pipeline / program updates (clinical, regulatory, manufacturing)
- People update (hiring, departures, comp issues)
- Strategic items (specific decisions or discussions for the board)
- Board resolutions (items requiring board vote)
- Appendices (deep data on programs, financials, etc.)
For a clinical-stage biotech, the pipeline section often dominates; reading it well is core competence for an MD director.
The Board Meeting Itself
A typical 3-hour board meeting:
| Segment | Time | Function |
|---|---|---|
| CEO opening | 15 min | High-level update; tone-setting |
| Programs / pipeline review | 60–75 min | Deep on each program; questions |
| Financial update | 30 min | Cash position, runway, planning |
| Strategic discussion | 30–45 min | Items requiring board input |
| Board resolutions | 10–15 min | Formal votes |
| Executive session | 15 min | Board only (no team) |
The IC dynamics: the CEO drives; investors-as-directors weigh in heavily on financial and strategic items; independent directors and clinical-MD directors often weigh in heavily on pipeline.
The Director's Job Between Meetings
The strong director does substantive work between meetings:
- Calls with the CEO 1–2 times between meetings
- Network introductions for the company
- Specific advisory work in the director's area of expertise
- Reading the company's relevant industry materials (papers, competitor announcements)
Boards that experience their members as "show up to meetings" are under-using their boards.
CEO-Board Relationship
The senior board member maintains a particular stance toward the CEO:
- Supportive but not deferential. Backs the CEO publicly; raises concerns privately first.
- Honest. Tells the CEO things their team won't.
- Available. Responds to CEO calls promptly.
- Forward-looking. Brings forward thinking, not just historical critique.
The board member who only critiques is unhelpful; the board member who only cheers is a rubber-stamp. The right stance is "thinking partner with fiduciary perspective."
Common Failure Modes
| Failure | Looks Like | Fix |
|---|---|---|
| Under-preparation | Reading the package the morning of | Read within 48 hours of distribution |
| Disengaged between meetings | Only shows up at quarterly meetings | Substantive between-meeting contribution |
| Domain over-reach | MD director second-guessing every clinical decision | Add value at the strategic / governance level; the team executes |
| Conflict ambiguity | Not disclosing apparent conflicts | Disclose freely; let the board decide |
| Public-private confusion | Disagreeing with CEO publicly | Disagree privately first; back publicly |
| Materials illiteracy | Doesn't understand financials, cap tables, term sheets | Build the literacy; cross-load with negotiation-leverage/equity-literacy |
Self-Coaching Track
For your situation (MD → biotech VC/operator, board-track potential):
Build fiduciary literacy. Read the basics on Delaware corporate law, director duties, conflict-of-interest standards. NACD (National Association of Corporate Directors) materials are the canonical primer.
Build financial / cap-table literacy. Cross-load with
negotiation-leverage/equity-literacyandinvesting/archon. A director who can't read a cap table is incompletely prepared.Read public board materials. Many public companies' board materials are partially disclosed in proxies. Read 3–5 to internalize the format.
Shadow a board if possible. Ask a friendly CEO if you can attend a board meeting as an observer. The live experience teaches faster than reading.
Prepare for the offer. When a board observer or director seat is offered, evaluate using the optionality / role frame; understand the time commitment, compensation, and liability implications before accepting.
For your first seat, default to high preparation. Read every package within 48 hours. Show up with 5+ substantive questions. Build between-meeting contribution from day 1.
Mentor up. Find an experienced board member who'll mentor you through your first year of board service. The compounding learning is enormous.
Teach / Mentor-Others Track
When coaching a junior or peer through board readiness:
The director-observer-advisor distinction matters. Mentees often conflate them. Walk through the table; the implications are different per role.
Fiduciary duties are not optional knowledge. Coach mentees to learn the basics before accepting any director seat. NACD materials are a good start.
The materials-discipline is the visible competence. Coach the 48-hour-read habit. Other directors will notice; the noticing compounds reputation.
Coach against domain over-reach. MD mentees on biotech boards often want to second-guess every clinical decision. Reframe: governance perspective, not execution; the team executes.
The CEO-board relationship is a craft. Walk through the supportive-but-not-deferential stance; rehearse the disagree-privately-back-publicly pattern.
Between-meeting contribution distinguishes the strong director. Coach mentees to plan substantive between-meeting work — calls, intros, advisory — from day 1.
When This Applies
- Considering a board observer or director seat offer
- Preparing for the first board meeting in a new role
- Preparing for board interactions in a CMO or operator role
- Building credibility toward future board candidacy
- Coaching others on board service
Cross-Domain Connections
- executive-presence/executive-communication — Board materials and discussions are exec-comm intensive
- executive-presence/meeting-mastery — Board meetings are a special meeting type
- negotiation-leverage/equity-literacy — Board work requires cap-table and financial literacy
- interview-mastery/executive-interview-prep — Board candidate interviews share elements
- investing/archon — VC-backed company board literacy inherits investing frameworks
- biotech-venture/asclepius — Clinical-stage biotech boards require asclepius-grade pipeline literacy
- trajectory-design/role-archetype-mapping — Board work is its own archetype